Dabigatran: ready for prime time?

被引：6
作者：
Karthikeyan, Ganesan [1 ]
Eikelboom, John W. [2 ]
Hirsh, Jack [2 ]
机构：
[1] All India Inst Med Sci, Dept Cardiol, Cardiothorac Sci Ctr, New Delhi 110029, India
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
来源：
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE | 2010年 / 120卷 / 04期
关键词：
atrial fibrillation; dabigatran; thrombin inhibitors; venous thromboembolism; DIRECT THROMBIN INHIBITOR; KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; ATRIAL-FIBRILLATION; DOUBLE-BLIND; APIXABAN; TRIAL; THROMBOPROPHYLAXIS; RIVAROXABAN; PREVENTION;
D O I：
10.20452/pamw.909
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Studies in high-risk surgical patients have demonstrated the efficacy of the selective inhibitors of factor Xa and thrombin in preventing venous thromboembolism. Because of their predictable dose-response, which eliminates the need for routine laboratory monitoring, they may be more convenient for patients requiring long-term therapy, and have the potential to improve the quality of anticoagulation. The results from 2 large trials of dabigatran (a thrombin inhibitor) compared to warfarin, in patients with atrial fibrillation and those with acute symptomatic venous thromboembolism, have recently become available. These trials provide convincing evidence of the efficacy of dabigatran in preventing patient-important clinical outcomes when compared to warfarin. In this paper we critically review these trials and discuss the feasibility of replacing warfarin with dabigatran for these indications.
引用
收藏
页码：137 / 142
页数：6
相关论文
共 13 条
  • [1] Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
    Alexander, John H.
    Becker, Richard C.
    Bhatt, Deepak L.
    Cools, Frank
    Crea, Filippo
    Dellborg, Mikael
    Fox, Keith A. A.
    Goodman, Shaun G.
    Harrington, Robert A.
    Huber, Kurt
    Husted, Steen
    Lewis, Basil S.
    Lopez-Sendon, Jose
    Mohan, Puneet
    Montalescot, Gilles
    Ruda, Mikhail
    Ruzyllo, Witold
    Verheugt, Freek
    Wallentin, Lars
    Darius, Harald
    Simoons, Maarten
    Boersma, Eric
    DeLemos, James
    Spencer, Fred
    [J]. CIRCULATION, 2009, 119 (22) : 2877 - U39
  • [2] The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
    Blech, Stefan
    Ebner, Thomas
    Ludwig-Schwellinger, Eva
    Stangier, Joachim
    Roth, Willy
    [J]. DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) : 386 - 399
  • [3] Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Yusuf, Salim
    Eikelboom, John
    Oldgren, Jonas
    Parekh, Amit
    Pogue, Janice
    Reilly, Paul A.
    Themeles, Ellison
    Varrone, Jeanne
    Wang, Susan
    Alings, Marco
    Xavier, Denis
    Zhu, Jun
    Diaz, Rafael
    Lewis, Basil S.
    Darius, Harald
    Diener, Hans-Christoph
    Joyner, Campbell D.
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) : 1139 - 1151
  • [4] Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement
    Eriksson, B. I.
    Kakkar, A. K.
    Turpie, A. G. G.
    Gent, M.
    Bandel, T. -J.
    Homering, M.
    Misselwitz, F.
    Lassen, M. R.
    [J]. JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2009, 91B (05): : 636 - 644
  • [5] Garcia D, 2009, BLOOD
  • [6] Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis
    Hart, RG
    Benavente, O
    McBride, R
    Pearce, LA
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) : 492 - +
  • [7] New oral anticoagulants: not quite there yet
    Karthikeyan, Ganesan
    Eikelboom, John W.
    Hirsh, Jack
    [J]. POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2009, 119 (1-2): : 53 - 58
  • [8] Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
    Lassen, Michael Rud
    Raskob, Gary E.
    Gallus, Alexander
    Pineo, Graham
    Chen, Dalei
    Hornick, Philip
    [J]. LANCET, 2010, 375 (9717) : 807 - 815
  • [9] Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
    Lassen, Michael Rud
    Raskob, Gary E.
    Gallus, Alexander
    Pineo, Graham
    Chen, Dalei
    Portman, Ronald J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (06) : 594 - 604
  • [10] Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
    Mega, J. L.
    Braunwald, E.
    Mohanavelu, S.
    Burton, P.
    Poulter, R.
    Misselwitz, F.
    Hricak, V.
    Barnathan, E. S.
    Bordes, P.
    Witkowski, A.
    Markov, V.
    Oppenheimer, L.
    Gibson, C. M.
    [J]. LANCET, 2009, 374 (9683) : 29 - 38
12